Gold prices cool after hitting over 2-week high on Fed independence fears
Investing.com -- Krystal Biotech , Inc. (NASDAQ:KRYS) reported second-quarter earnings and revenue that surpassed analyst expectations, driven by strong sales of its VYJUVEK treatment for dystrophic epidermolysis bullosa (DEB). The biotech company posted adjusted earnings per share of $1.29, beating the analyst estimate of $1.22, while revenue reached $96.04 million, exceeding the consensus forecast of $92.24 million.
The company’s quarterly revenue represented a 36.6% increase compared to the $70.3 million reported in the same quarter last year. Following the announcement, Krystal Biotech shares jumped 3.8% as investors responded positively to the earnings and revenue beat.
"With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech.
The company reported that it has secured over 575 reimbursement approvals for VYJUVEK in the U.S. and maintains strong nationwide access. Patient compliance with weekly treatment while on the drug was 82% as of the end of the quarter. Gross margin for the quarter was 93%.
Krystal Biotech is preparing to launch VYJUVEK in Japan before the end of 2025 following approval by Japan’s Ministry of Health, Labour and Welfare in July. The company is also working to enable its first European launches in Germany in the third quarter and France in the fourth quarter.
The company ended the quarter with a strong financial position, reporting $820.8 million in cash, cash equivalents, and investments as of June 30, 2025. Net income for the quarter was $38.3 million, compared to $15.6 million in the same period last year.
Krystal Biotech maintained its full-year 2025 guidance for non-GAAP research and development and selling, general and administrative expenses of $150 million to $175 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.